跳至主要内容
临床试验/NCT03484091
NCT03484091已完成4 期

Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis: A Randomized Double-blind, Saline-controlled Trial

Thammasat University1 个研究点 分布在 1 个国家目标入组 276 人开始时间: 2018年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
276
试验地点
1
主要终点
Pain level

研究概览

简要总结

We compare the efficacy of intra-articular injection of Hyruan-One with Hylan G-F 20 and placebo (NSS) controlled in a double-blind RCT.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptomatic primary knee osteoarthritis with failed conservative treatment for at least 3 months
  • Gave informed consent
  • Can do questionnaires

排除标准

  • Severe deformity (varus or valgus from a mechanical axis more than 10 degrees
  • Allergy to hyaluronic acid
  • Pain in the hip or ankle
  • Post-traumatic or post surgery of lower extremity
  • Post-infection of the knee
  • Previous hyaluronic acid injection within 6 months
  • Pregnancy or lactation
  • Underlying Rheumatoid arthritis, stroke, malignancy, venous occlusion

研究组 & 干预措施

H group

Experimental

Single dose of Hyruan-One 3 mL intra-articular knee injection.

干预措施: Hyruan-One (Drug)

S group

Active Comparator

Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.

干预措施: Hylan G-F 20 (Drug)

N group

Placebo Comparator

Single dose of normal saline 6 mL intra-articular knee injection.

干预措施: Normal saline (Drug)

结局指标

主要结局

Pain level

时间窗: 6 months after injection

visual analog scale for pain (0-100) in between groups

Change from pre-injection pain level at 6 months

时间窗: 6 months

compare visual analog scale for pain (0-100) between pre-injection and post-injection

次要结局

  • Time up and go test(post-injection 1, 3, 6 months)
  • pain level in any time pints(post-injection 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks)
  • Modified WOMAC(post-injection 2 weeks, 1, 2, 3,4, 5, 6 months)
  • Lequesne index(post-injection 2 weeks, 1, 2, 3,4, 5, 6 months)
  • SF-36(post-injection 2 weeks, 1, 2, 3,4, 5, 6 months)
  • Complications(post-injection 1, 2 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Supakit Kanitnate

Department of orthopaedics

Thammasat University

研究点 (1)

Loading locations...

相似试验